An HIV-positive person who takes anti-retroviral drugs after diagnosis, rather than when their health declines, can cut the risk of spreading the virus to uninfected partners by 96%, according to a study.
The United States National Institutes of Health sampled 1,763 couples in which one partner was infected by HIV. It was abandoned four years early as the trial was so successful. The World Health Organization said it was a "crucial development".
Anti-retroviral drugs 'help reduce' HIV transmission
Thought Bed Bugs Were Bad? Try Bed Bugs With MRSA
The one bright side of having bed bugs — if you wanted to be really optimistic about it — has always been that at least the tormenting critters didn't transmit disease. But now researchers in Vancouver report that they've found bed bugs with methicillin-resistant Staphylococcus aureus, or MRSA.
The scientists studied five bed bugs, taken from three patients treated at St. Paul's Hospital. All three patients were residents of Vancouver's poor Downtown Eastside, where both bed bugs and MRSA have been on the rise in recent years. The researchers wanted to see if there was a connection.
Study Reveals 83 Individuals with Autism Quietly Compensated by Federal Vaccine Injury Court
National Autism Association Calls for Immediate Congressional and Scientific Investigation Into Autism-Vaccine Link
Despite numerous studies cited repeatedly by federal officials as proof that vaccines do not cause autism, a new study released today in the Pace Environmental Law Review revealed that over the last two decades, the National Vaccine Injury Compensation Program (NVICP) has been quietly compensating dozens of vaccine injury cases involving a child with autism. The preliminary findings showed approximately 1300 cases of vaccine injury resulted in childhood brain injury, 83 of which had autism. The National Autism Association (NAA) says the study further underscores the need for Congressional hearings and independent scientific research into the autism-vaccine connection.
Investigators Find Clear Vaccine-Autism Link Based on Government Data
The Elizabeth Birt Center for Autism Law and Advocacy (EBCALA) held a press conference in front of the U.S. Court of Federal Claims to release a study linking vaccine injury to autism. For over 20 years, the federal government has denied a vaccine-autism link, while at the same time its Vaccine Injury Compensation Program has been awarding damages for vaccine injury to children with brain damage, seizures and autism. Coming out just after the prevalence study of autism in South Korea, this investigation breaks new ground in the controversial vaccine-autism debate.
Autism May Be Far More Common, Study Suggests
An exhaustive study of autism in one community has found that the disorder is far more common than suggested by earlier research. The study of 55,000 children in Goyang, South Korea, found that 2.64 percent — one in every 38 children — had an autism spectrum disorder.
"That is two and a half times what the estimated prevalence is in the United States," says Roy Richard Grinker, a professor of anthropology at The George Washington University and one of the study's authors.
Doctors' groups welcome medical company dollars
From the time they arrived to the moment they laid their heads on hotel pillows, the thousands of cardiologists attending this week's Heart Rhythm Society conference have been bombarded with pitches for drugs and medical devices.
St. Jude Medical adorns every hotel key card. Medtronic ads are splashed on buses, banners and the stairs underfoot. Logos splay across shuttle bus headrests, carpets and cellphone-charging stations. And at night, a drug firm gets the last word: A promo for the heart drug Multaq stood on each doctor's nightstand Wednesday.
Who arranged this commercial barrage? The society itself, which sold access to its members and their purchasing power.
Pancreatic Cancer Drug Afinitor Approved By FDA
Pancreatic cancer drug Afinitor by Novartis AG's has been approved by the U.S. FDA for a rare type of pancreatic cancer that has few treatment options, reports Reuters. The Swiss drugmaker said in a statement, "Data show Afinitor delays tumor growth and reduces risk of disease progression in patients with advanced neuroendocrine tumours (NET) of pancreatic origin."
"This marks the first approval of a treatment for this patient population in the United States in nearly 30 years," they added, Reuters reports.
More Articles...
Page 108 of 234